We focus on developing lower-risk tobacco products for adult tobacco consumers as part of a comprehensive approach to reduce the harm caused by tobacco products. The Scientific Strategy Advocacy Group generates the scientific evidence needed to demonstrate that certain tobacco products result in lower exposure to harmful compounds or are lower risk when compared to conventional cigarettes. We conduct clinical studies using the best practices (Good Clinical Practices) adopted from pharmaceutical clinical trials. We have been at the forefront of developing new methodologies to assess the health impact of potentially reduced harm tobacco products.
We've published extensively in this area and our work is often cited by other scientists including those at the FDA. We've also been involved in groundbreaking research to help the company and the science move forward. We share this research on a website where we invite scientific review from and dialogue with scientists and the public health and regulatory communities.